Top 4 Health Care Stocks That May Rocket Higher This Month
Top 4 Health Care Stocks That May Rocket Higher This Month
Read More: Vertex Pharmaceuticals, Gilead Sciences And 2 Other Stocks Insiders Are Selling The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
医疗保健领域超卖次数最多的股票为买入被低估的公司提供了机会。
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30.
RSI是一种动量指标，它比较了股票在价格上涨的日子里的强度与价格下跌时的强度。与股票的价格走势相比，它可以让交易者更好地了解股票在短期内的表现。当 RSI 低于 30 时，资产通常被视为超卖。
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
以下是该行业主要超卖参与者的最新名单，RSI接近或低于30。
Spruce Biosciences, Inc. (NASDAQ:SPRB)
斯普鲁斯生物科学公司 （纳斯达克股票代码：SPRB）
- Spruce Biosciences completed target enrollment of CAHmelia-203 study in adult classic congenital adrenal hyperplasia. The company's stock has a 52-week low of $0.9550 .
- RSI Value: 27.25
- SPRB Price Action: Shares of Spruce Biosciences fell 14.2% to close at $1.18 on Thursday.
- Spruce Biosciences完成了针对成人典型先天性肾上腺增生症的Cahmelia-203研究的目标入组。该公司的股票有 52 周低点 0.9550 美元 。
- RSI 值： 27.25
- SPRB 价格走势： 周四，Spruce Biosciences股价下跌14.2％，收于1.18美元。
Generation Bio Co. (NASDAQ:GBIO)
Generation Bio （纳斯达克股票代码：GBIO）
- TD Cowen downgraded the stock from Outperform to Market Perform. It has a 52-week low of $1.17.
- RSI Value: 16.32
- GBIO Price Action: Shares of Generation Bio dipped 50.2% to close at $1.20 on Thursday.
- 道明考恩将该股的评级从跑赢大盘下调至市场表现。它 创下 52 周低点 1.17 美元的。
- RSI 值： 16.32
- GBIO 价格走势： 周四，Generation Bio股价下跌50.2％，收于1.20美元。
LumiraDx Limited (NASDAQ:LMDX)
LumiRadX 有限公司 （纳斯达克股票代码：LMDX）
- LumiraDx posted downbeat results for the second quarter. Ron Zwanziger, Chairman and CEO of LumiraDx, stated, "The submission of our first 510(k) application to the FDA for our COVID Ultra test represents a significant milestone in our ability to deliver on product expansion into the U.S. and could pave the way for additional submissions of other high performing assays on our Platform, many of which are already available in Europe and elsewhere and others which are in late stages of development." The company's stock has a 52-week low of $0.0850.
- RSI Value: 19.64
- LMDX Price Action: Shares of LumiraDx fell 11.3% to close at $0.0930 on Thursday.
- LumiRadX公布了第二季度的悲观业绩。LumiRadX董事长兼首席执行官罗恩·兹万齐格表示：“我们向美国食品药品管理局提交了第一份510（k）COVID Ultra测试申请，这是我们向美国扩展产品能力的一个重要里程碑，可能为在我们平台上提交更多其他高性能检测方法铺平道路，其中许多已经在欧洲和其他地方上市，还有一些处于开发后期阶段。”该公司的股票持仓时间为52周 低点为0.0850美元。
- RSI 值： 19.64
- LMDX 价格走势： 周四，LumiRadX股价下跌11.3％，收于0.0930美元。
Evelo Biosciences, Inc. (NASDAQ:EVLO)
Evelo Biosciences, Inc （纳斯达克股票代码：EVLO）
- Evelo Biosciences reported the primary endpoint in its Phase 2 clinical study with EDP2939 in moderate psoriasis was not achieved. The company also initiated a process to explore strategic alternatives. The company's 52-week low is $0.48.
- RSI Value: 20.36
- EVLO Price Action: Shares of Evelo Biosciences fell 11.2% to close at $0.8883 on Thursday.
- Evelo Biosciences报告说，其在中度牛皮癣中使用 EDP2939 进行的 2 期临床研究的主要终点尚未实现。该公司还启动了探索战略替代方案的进程。该公司的52周低点为0.48美元。
- RSI 值： 20.36
- EVLO 价格走势： 周四，Evelo Biosciences股价下跌11.2％，收于0.8883美元。
Read More: Vertex Pharmaceuticals, Gilead Sciences And 2 Other Stocks Insiders Are Selling
阅读更多： Vertex Pharmicals、Gilead Sciences 和其他两只股票内部人士正在
